Dr Mike Tremblay

This is another article in my continuing commentary on market access and politics. The focus in this case is to look more closely at behaviours of people involved from government, industry and healthcare. Occupying these roles are people who bring their own psychological perspective to how they apply their knowledge and skills to their work. […]

Market access is wrapped in the politics of health The attention politicians and stakeholders pay to healthcare and its challenges is a keen driver of the ease or difficulty companies experience with drug regulation and market access and has implications through the development process to discovery. How this manifests itself, in part depends on a […]

We are in a new world when it comes to access to and the use of data and evidence. Real world data and evidence takes us from structured studies to the routine delivery of healthcare, actual use of a medicine, and the patient’s actual health status. What is knowing this worth and to whom? Real […]

The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in multiple years of costed care so industry needs to assess how that can be understood […]